2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 226

Representation of Elderly People and Women in Rheumatoid Arthritis and Osteoarthritis Trials: A Systematic Review and Meta-Analysis Comparing Clinical Trials with Population-Based Studies
Abstract Number: 2700

Rescuing Standard Analyses of Immunosuppresive Rescue Therapy in Randomized Controlled Trials: Alternative Approaches in a Scleroderma Clinical Trial
Abstract Number: 1430

Research Priorities for Addressing Mental Health Needs of Pediatric Patients with Rheumatologic Disease
Abstract Number: 1972

Resolving the Synovial Fluid Proteome and Peptidome for Disease-Specific Mediators of Inflammatory Arthritis
Abstract Number: 1316

Respiratory Involvement in Relapsing Polychondritis – a Single Centre Study
Abstract Number: 2085

Response Gene to Complement-32 Promotes Kidney Damage in Immune Complex –Mediated Glomerulonephritis
Abstract Number: 2303

Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed By Alendronate
Abstract Number: 1404

Responsiveness of Promis (Patient Reported Outcomes Measurement Information System) Measures in a Multi-Racial, Multi-Ethnic Systemic Lupus Erythematosus (SLE) Cohort
Abstract Number: 1165

Restless Sleep Trajectories over 8 Years: Data from the Osteoarthritis Initiative
Abstract Number: 2387

Resurrecting Triamcinolone Hexacetonide (the Steroid Formerly Known as Aristospan®): Efficacy and Safety of a Compounded Preparation of Triamcinolone Hexacetonide for Intra-Articular Injection in Children with Arthritis
Abstract Number: 2543

Retention Rate and Safety Data of Biosimilar CT-P13 in Patients with Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Abstract Number: 1781

Retrospective Analysis of IgG4-RD Patient Population at the Cleveland Clinic between 2007-2017
Abstract Number: 1796

Retrospective Analysis of Initial Presentation Findings of Behcet’s Syndrome throughout 4 Decades
Abstract Number: 2139

Retrospective Study: Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase (G6PD)
Abstract Number: 2526

Revealing and Addressing Knowledge Gaps Regarding Biosimilars in Rheumatology Practice with Targeted Continuing Education and Patient Surveys

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].